Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01079780 |
|
Recruitment Status :
Completed
First Posted : March 3, 2010
Results First Posted : June 10, 2022
Last Update Posted : June 10, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and ramucirumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab and ramucirumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. It is not yet know whether giving cetuximab and irinotecan hydrochloride together is more effective with or without ramucirumab in treating colorectal cancer.
PURPOSE: This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Cancer | Biological: cetuximab Biological: ramucirumab Drug: irinotecan hydrochloride | Phase 2 |
OBJECTIVES:
- To evaluate the progression-free survival of patients with advanced K-ras wild-type colorectal cancer, following progression on bevacizumab-contained chemotherapy, treated with irinotecan hydrochloride and cetuximab with versus without ramucirumab as second-line therapy.
- To evaluate the response rate in patients treated with these regimens.
- To evaluate the grade 3-4 toxicity rates of these regimens in these patients.
- To evaluate the overall survival of patients treated with these regimens.
OUTLINE: This is a multicenter, randomized study. Patients are stratified according to performance status (0 vs 1), discontinuation of oxaliplatin before disease progression (yes vs no), and time to disease progression since last treatment (≤ 6 months vs > 6 months). Patients are randomized to 1 of 2 treatment arms.
- Arm A: Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride over 60-90 minutes on day 1.
- Arm B: Patients receive ramucirumab IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm A. Arm B was closed early due to excessive toxicities and Arm C was then added to the study with reduced dose of protocol drugs.
- Arm C: Patients receive reduced dose of ramucirumab, cetuximab and irinotecan hydrochloride as in arm B.
In all arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up periodically for 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 136 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy |
| Actual Study Start Date : | October 8, 2010 |
| Actual Primary Completion Date : | February 22, 2021 |
| Actual Study Completion Date : | August 17, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Arm A (IC)
Patients receive cetuximab (500 mg/m2) intravenously (IV) over 60-120 minutes and irinotecan hydrochloride (180 mg/m2) over 60-90 minutes on day 1. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
|
Biological: cetuximab
Given IV
Other Names:
Drug: irinotecan hydrochloride Given IV
Other Name: Irinotecan hydrochloride trihydrate |
|
Experimental: Arm B (ICR)
Patients receive ramucirumab (8 mg/kg) IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm A. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
|
Biological: cetuximab
Given IV
Other Names:
Biological: ramucirumab Given IV
Other Names:
Drug: irinotecan hydrochloride Given IV
Other Name: Irinotecan hydrochloride trihydrate |
|
Experimental: Arm C (mICR)
Patients receive reduced dose of ramucirumab (6 mg/kg) IV over 60 minutes on day 1 and cetuximab (150 mg/m2) and irinotecan hydrochloride (400 mg/m2) as in arm B. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
|
Biological: cetuximab
Given IV
Other Names:
Biological: ramucirumab Given IV
Other Names:
Drug: irinotecan hydrochloride Given IV
Other Name: Irinotecan hydrochloride trihydrate |
- Progression-free Survival [ Time Frame: Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years ]
Progression-fee survival is defined as the time from randomization to disease progression or death without documentation of progression. Censoring occurred at the date of last disease assessment without progression for cases without documentation of progression, except for cases where death occurred within a short period of time (4 months) following the date last known progression-free, in which case the death was considered an event.
Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
- Proportion of Participants With an Objective Response Rate (CR or PR) [ Time Frame: Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years ]Objective response is defined as either complete response or partial response. Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
- Proportion of Patients With Grade 3 or Higher Treatment-related Adverse Events [ Time Frame: Assessed every 2 weeks while on treatment and for 30 days after the end of treatment ]Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE). Treatment-related adverse events are defined as those that are possibly, probably, or definitely related to protocol therapy.
- Overall Survival [ Time Frame: Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years ]Overall survival is defined as the time from randomization to death or date last known alive.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Measurable disease
- Histologically confirmed adenocarcinoma of the colon or rectum
- K-ras wild type based on either primary or metastatic tumor
- Must have received prior first-line therapy comprising oxaliplatin-based fluoropyrimidine-containing chemotherapy and bevacizumab for metastatic colorectal cancer
- Registration within 42 days since confirmed disease progression
- Performance status 0-1
- ANC ≥ 1,500/μL
- Platelet count ≥ 75,000/μL
- Hemoglobin ≥ 9 g/dL
- Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 40 mL/min
- Urine protein ≤ 1+ on dipstick or routine urinalysis (if ≥ 2+, a 24-hour urine collection must demonstrate < 1,000 mg of protein)
- Total bilirubin ≤ 2.0 mg/dL
- AST and ALT ≤ 3.0 times ULN (5.0 times ULN for patients with liver metastases)
- INR ≤ 1.6 (≤ 3.0 for patients on warfarin and no active bleeding [i.e., no bleeding within the past 14 days])
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study therapy
- At least 28 days and no more than 90 days since prior bevacizumab
- Concurrent stable dose of oral anticoagulant or low-molecular weight heparin allowed
Exclusion Criteria:
- Brain or CNS metastases
- Pregnant or nursing
- Prior therapy with drugs other than oxaliplatin and a fluoropyrimidine plus bevacizumab for colorectal cancer
- Clinically significant (equivalent to NCI CTCAE grade 3-4) bleeding episodes within the past 3 months
- Active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Symptomatic or poorly controlled cardiac arrhythmia
- Uncontrolled thrombotic or hemorrhagic disorder
- Uncontrolled or poorly controlled hypertension despite standard medical management (e.g., consistently systolic BP > 160 mm Hg and diastolic BP > 90 mm Hg)
- Acute arterial thrombotic events within the past 6 months, including cerebrovascular accident, transient ischemic attack, myocardial infarction, or unstable angina
- Other cancer requiring therapy within the past 3 years except in situ carcinoma or nonmelanoma skin cancer
- Acute or subacute intestinal obstruction
- History of inflammatory bowel disease requiring pharmacological and/or surgical intervention within the past 12 months
- Known allergy to any of the treatment components
- Major surgery within the past 28 days
- Subcutaneous venous access device placement within the past 7 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01079780
Show 255 study locations
| Principal Investigator: | Howard S. Hochster, MD | NYU Langone Health |
Documents provided by Eastern Cooperative Oncology Group:
| Responsible Party: | Eastern Cooperative Oncology Group |
| ClinicalTrials.gov Identifier: | NCT01079780 |
| Other Study ID Numbers: |
E7208 CDR0000666736 |
| First Posted: | March 3, 2010 Key Record Dates |
| Results First Posted: | June 10, 2022 |
| Last Update Posted: | June 10, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy. |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
mucinous adenocarcinoma of the colon recurrent colon cancer signet ring adenocarcinoma of the colon stage III colon cancer stage IV colon cancer |
mucinous adenocarcinoma of the rectum recurrent rectal cancer signet ring adenocarcinoma of the rectum stage III rectal cancer stage IV rectal cancer |
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Rectal Diseases Irinotecan Cetuximab Ramucirumab Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antineoplastic Agents, Immunological |